王晶晶;王超;刘敏;李鹏辉;谢颂扬;吴莉莉;

• 1:河南省人民医院省直第一医院
• 2:河南省人民医院

摘要(Abstract)：

目的评价血小板功能检测在高血压合并急性脑梗死非溶栓患者的抗栓治疗监测中的应用价值,探讨抗血小板药物治疗反应多样性。方法选择335例于2018-01—2019-06住院的未溶栓的确诊高血压合并急性脑梗死患者为研究对象,根据不同的抗血小板药物种类和剂量分组:阿司匹林200mg治疗组、阿司匹林100mg治疗组、氯吡咯雷治疗组、替格瑞洛治疗组。采用比浊法分别检测各组治疗前后AA、ADP、Col、EPI诱导的MAR。结果治疗7d后,各治疗组MARADP、MARAA、MARCol、MAREPI较治疗前均下降,差异有统计学意义(P<0.05)。氯吡格雷治疗组及替格瑞洛治疗组MARADP差值高于不同剂量阿司匹林治疗组,差异有统计学意义(P<0.05)。不同剂量阿司匹林治疗组MARAA差值均高于氯吡格雷治疗组及替格瑞洛治疗组,差异有统计学意义(P<0.05);阿司匹林200mg治疗组MARAA差值高于阿司匹林100mg治疗组,差异有统计学意义(P<0.05)。结论阿司匹林、氯吡咯雷、替格瑞洛均能有效降低高血压合并急性脑梗死非溶栓患者的血小板最大聚集率,阿司匹林200mg比阿司匹林100mg剂量的抗血小板效果更佳。

关键词(KeyWords)： 脑梗死;血小板功能检测;血小板最大聚集率;抗栓治疗;血小板药物治疗反应多样性

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(编号:81570274)

作者(Authors): 王晶晶;王超;刘敏;李鹏辉;谢颂扬;吴莉莉;

参考文献(References)：

• [1]FURUTA T,SUGIMOTO M,KODAIRA C,et al.Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel[J].J Thromb Thrombolysis,2017,43(3):333-342.DOI:10.1007/s11239-016-1460-2．
• [2]FORTUNA L A,PAWLOSKI P A,PARKER E D,et al.Proton pump inhibitor use by aspirin-treated coronary disease patients is not associated with increased risk of cardiovascular events[J].Eur Heart J Cardiovascular Pharmacotherapy,2016,2(1):13-19.DOI:10.1093/ehjcvp/pvv036．
• [3]MORETTI A,FERRARI F,VILLA R F.Pharmacological therapy of acute ischemic stroke:Achievements and problems[J].Pharmacol Ther,2015,153:79-89.DOI:10.1016/j.pharmthera.2015.06.004．
• [4]于建华，王运良．抗血小板药物抵抗与复发性缺血性脑卒中[J]．中国实用神经疾病杂志，2017,20(16):113-116．
• [5]YI X,LIN J,WANG Y,et al.Response to clopidogrel is associated with early neurological deterioration after acute ischemic stroke[J].Oncotarget,2018,9:19900-19910.DOI:10.18632/oncotarget.24945．
• [6]LI W,LIN L,ZHANG M,et al.Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients[J].Stroke,2016,47:2649-2651.DOI:10.1161/STROKEAHA.116.014413．
• [7]FENG L,LIU J,LIU Y,et al.Tirofiban combined with urokinase selective intra-arterial thrombolysis for the treatment of middle cerebral artery occlusion[J].Exp Ther Med,2016,11:1011-1016.DOI:10.3892/etm.2016.2995．
• [8]TSIVGOULIS G,KATSNAOS A H,ZAND R,et al.Anti-platelet pretreatment and outcomes in intravenous thrombolysis for stroke:a systematic review and meta-analysis[J].J Neurol,2017,264(6):1227-1235.DOI:10.1007/s00415-017-8520-1．
• [9]WANG X,ZHAO X,JOHNSTON S C,et.al.Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke:CHANCE substudy[J].Neurology,2015,85(7):573-579.DOI:10.1212/WNL.0000000000001844．
• [10]STERGIOPOULOS K,VASU S,BILFINGER T,et al.Embolic stroke in a patient with metastatic renal cell[J].Hellenic J Cardiol,2011,52(3):225-256.DOI:10.1016/j.hrthm.2011.03.040．
• [11]杨阿莉，胡亚梅，向莉，等．进展性缺血性脑卒中与阿司匹林抵抗及PEAR1基因型的相关性研究[J]．中国实用神经疾病杂志，2019,22(1):1-5.DOI:10.12083/SYSJ.2019.01.001．
• [12]JIVAN K,RANCHOD K,MODI G.Management of ischemic stroke in the acute setting:review of the current status[J].Cardiovasc J Afr,2013,24(3):86-92.DOI:10.5830/CVJA-2013-001．
• [13]WANG Y,MINEMATSU K,WONG K S,et al.Ticagrelor in acute stroke or transient ischemic attack in asian patients:from the SOCRATES Trial(Acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes)[J].Stroke,2017,48(1):167-173.DOI:10.1161/STROKEAHA.116.014891．
• [14]GEEGANAGE C M,DIENER H C,ALGRA A,et al.Dual or mono-anti-platelet therapy for patients with acute ischemic stroke or transient ischemic attack systematic review and mete-analysis of randomized controlled trials[J].Stroke,2012,43(4):1058.DOI:10.1161/STROKEAHA.111.637686．
• [15]AMARENCO P,ALBERS G W,DENISON H,et al.Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischemic attack of atherosclerotic origin:a subgroup analysis of SOCRATES,a randomized double-blind,controlled trial[J].Lancet Neurol,2017,16(4):301-310.DOI:10.1016/S1474-4422(17)30038-8．
• [16]ZHANG L Y,YUAN Y Q,ZHOU D M,et al.Impact of global and gene-specific DNA methylation in denovo or relapsed acute myeloid leukemia patients treated with Decitabine[J].Asian Pat J Cancer Prev,2016,17(1):431-437.DOI:10.7314/apjcp.2016.17.1.431．
• [17]PAN X,ZHU Y,ZHENG D,et al.Prior anti-platelet agent use and outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke:a meta-analysis of cohort studies and randomized controlled trials[J].Int J Stroke,2015,10(3):317-323.DOI:10.1111/ijs.12431．
• [18]GREISENEGGER S,SEYFANG L,KIECHL S,et al.Thrombolysis in patients with mild stroke:results from the Austrian Stroke Unit Registry[J].Stroke,2014,45(3):765-769.DOI:10.1161/STROKEAHA.113.003827．
• [19]FIELD T S,BENAVENTE O R.Current status of antiplatelet agents to prevent stroke[J].Curr Neurosci Rep,2011,11(1):6-14.DOI:10.1007/s11910-010-0162-y．
• [20]ROBINSON T G,WANG X,ARIMA H,et al.Lowversus standard dose alteplase in patients on prior antiplatelet therapy:The ENCHANTED Trial(Enhanced Control of Hypertension and Thrombolysis Stroke Study)[J].Stroke,2017,48(7):1877-1883.DOI:10.1161/STROKEAHA.116.016274．
• [21]AMIN A M,SHEAU CHIN L,MOHAMED NOOR DA,et al.The effect of CYP2C19genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary disease patients[J].Thromb Res,2017,158(10):22-24.DOI:10.1016/j.thromres.2017.07.032.